Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 September 2021Website:
http://www.tyra.bioNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:30:56 GMTDividend
Analysts recommendations
Institutional Ownership
TYRA Latest News
- In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein - -TYRA remains on track to submit ACH Investigational New Drug Application (IND) in 2H24- CARLSBAD, Calif. , July 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced preclinical proof-of-concept results with TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH).
Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, May 28-29, 2024 : Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, May 28, 2024, at 1:00 pm ET.
The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet.
Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What type of business is Tyra Biosciences?
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
What sector is Tyra Biosciences in?
Tyra Biosciences is in the Healthcare sector
What industry is Tyra Biosciences in?
Tyra Biosciences is in the Biotechnology industry
What country is Tyra Biosciences from?
Tyra Biosciences is headquartered in United States
When did Tyra Biosciences go public?
Tyra Biosciences initial public offering (IPO) was on 15 September 2021
What is Tyra Biosciences website?
https://www.tyra.bio
Is Tyra Biosciences in the S&P 500?
No, Tyra Biosciences is not included in the S&P 500 index
Is Tyra Biosciences in the NASDAQ 100?
No, Tyra Biosciences is not included in the NASDAQ 100 index
Is Tyra Biosciences in the Dow Jones?
No, Tyra Biosciences is not included in the Dow Jones index
When does Tyra Biosciences report earnings?
The next expected earnings date for Tyra Biosciences is 09 August 2024